Second Chance at Life Act of 2025
- Sponsor
- Rep. Pfluger, August [R-TX-11]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Sep 18, 2025
Bottom line
The bill seeks to expand informed consent requirements for chemical abortions by mandating information about abortion pill reversal, a practice whose scientific validity is debated.
What it actually does
This bill mandates that abortion providers inform women seeking a chemical abortion about the possibility of reversing the effects of mifepristone if they change their mind before taking the second pill (misoprostol). It requires verbal and written notice, conspicuous signage in facilities, and the Department of Health and Human Services (HHS) to create a website with information and resources on abortion pill reversal. The bill also establishes civil remedies, allowing the woman, the father of the unborn child, or a parent of a minor woman to sue providers for non-compliance.
Proponents argue
Proponents argue that this bill ensures women have complete information about all available options, including the possibility of reversing a chemical abortion, empowering them to make fully informed decisions. They contend that providing this information offers a 'second chance' to women who may regret their initial decision and wish to continue their pregnancy, emphasizing the importance of informed consent and patient autonomy.
Opponents contend
Opponents contend that the bill mandates the dissemination of medically unproven information, potentially misleading women and delaying necessary medical care. They argue that the concept of 'abortion pill reversal' is not supported by robust scientific evidence and that requiring providers to present it as a viable option is coercive and designed to deter women from accessing abortion, infringing on medical ethics and patient-provider trust.
The bill is relatively short and straightforward, making it accessible for an informed reader to understand its core provisions within a reasonable timeframe.
Section 1
Short Title
This section formally names the Act as the 'Second Chance at Life Act of 2025.' This title clearly communicates the bill's intent to provide an opportunity for women to reconsider and potentially reverse a chemical abortion.
Supporters argue
Supporters argue that the title accurately reflects the bill's compassionate goal of offering women a chance to reconsider their decision and potentially save their pregnancy.
Critics contend
Critics may argue that the title is misleading, as it implies a medically proven 'second chance' that is not universally accepted by the medical community.
Tradeoffs
The title frames the bill's purpose in a way that aligns with its proponents' views, potentially influencing public perception of the legislation's intent and medical basis.
Section 2, Title XXXIV, Sec. 3402(b)
Abortion Pill Reversal Informed Consent Requirement
This provision mandates that before a chemical abortion involving mifepristone and misoprostol, the woman must be informed, at least 24 hours prior, that it may be possible to reverse the effects of mifepristone if she changes her mind. This information must be provided by a physician or their agent, either by telephone or in person. Additionally, after the first pill (mifepristone) is dispensed, written discharge instructions must be given, stating that recent research indicates mifepristone alone is not always effective and reversal may be possible if the second pill has not been taken, advising immediate consultation with a healthcare professional.
Section 2, Title XXXIV, Sec. 3403
Exception for Medical Emergencies
This section provides an exception to the informed consent requirements for chemical abortions in cases of medical emergency. A medical emergency is defined as a physical disorder, injury, or illness that would place the woman in danger of death unless an abortion is performed, including life-endangering conditions arising from the pregnancy itself. In such cases, the abortion provider must include a truthful and accurate certification of the specific medical circumstances in the woman's medical file.
Section 2, Title XXXIV, Sec. 3404
Sign Posting Requirement
Any facility performing chemical abortions (excluding those solely for medical emergencies) must conspicuously post a sign in patient waiting rooms, consultation rooms, or admission areas. The sign must state: 'Research has indicated that mifepristone alone is not always effective in ending a pregnancy and that its effects can be blocked or reversed if the second pill has not yet been taken. If you change your mind prior to taking the second pill and desire to attempt to save your pregnancy, consult with a health care professional immediately.' The lettering must be legible and at least three-quarters of an inch boldfaced type.
Section 2, Title XXXIV, Sec. 3405
HHS Website and Printed Information
This section requires the Secretary of Health and Human Services (HHS) to publish and make available printed materials, both online and physically, designed to inform women about the possibility of reversing a mifepristone-induced chemical abortion and the assistance/resources available for such reversal. HHS must develop and maintain a website within 30 days of enactment, providing this information in English and other major state languages. The website must not collect user data, be regularly monitored for tampering, and meet specific technical standards for resolution, picture size, font size, and browser accessibility.
Section 2, Title XXXIV, Sec. 3406
Civil Remedies for Violations
This section establishes civil remedies, allowing specific parties to bring a civil action in federal district court against an abortion provider who knowingly or recklessly violates the informed consent requirements. Eligible plaintiffs include the woman upon whom the abortion was performed or attempted, the father of the unborn child, or a parent of a minor woman or a woman who died as a result of the abortion. A plaintiff cannot bring suit if the pregnancy resulted from their own criminal conduct. Prevailing plaintiffs are awarded reasonable attorney's fees, and prevailing defendants can receive attorney's fees if the action was frivolous or brought in bad faith.
The term 'unborn child' is defined as 'a member of the species homo sapiens, at any stage of development prior to birth.'
Section 2, Title XXXIV, Sec. 3401(3)
Why it matters:This is standard legislative practice to define terms upfront, but the broadness of the definition has significant implications for how the bill frames the subject of abortion.
Case for: Proponents argue this definition reflects a scientific and moral understanding of human life beginning at conception, aligning with the bill's intent to protect potential life.
Case against: Opponents argue this broad definition is a strategic legal move to establish fetal personhood at all stages of development, which could have far-reaching implications beyond this bill for abortion rights and reproductive healthcare.
Estimated impact: This definition underpins the entire bill's premise regarding the 'unborn child' as the subject of the abortion, influencing legal interpretation and future legislative efforts.
The Act explicitly states that it does not preempt any State law that establishes more extensive disclosure requirements regarding abortion or penalties for non-compliance.
Section 3
Why it matters:This is a standard legislative practice for federal bills to clarify their relationship with state laws, but it's crucial for understanding the full regulatory landscape.
Case for: Proponents argue this ensures states retain their authority to enact stronger protections or disclosure requirements, allowing for a more robust regulatory environment where desired.
Case against: Opponents might argue that this clause allows for a patchwork of potentially conflicting or overly burdensome state regulations, further complicating abortion access and provider compliance.
Estimated impact: This provision ensures that the federal requirements set a floor, not a ceiling, for abortion disclosure laws, potentially leading to varied and more stringent regulations at the state level.
The civil remedies section grants standing to 'A father of an unborn child who is the subject of such a chemical abortion' to bring a civil action against an abortion provider.
Section 2, Title XXXIV, Sec. 3406(a)(2)
Why it matters:While part of the enforcement mechanism, granting standing to non-patients (fathers) is a significant expansion of legal rights in this context, which might be less emphasized than the direct patient-provider mandates.
Case for: Proponents argue that fathers have a legitimate interest in the outcome of a pregnancy and should have legal recourse if a provider fails to provide information that could have led to the continuation of the pregnancy.
Case against: Opponents argue that granting standing to fathers could lead to vexatious litigation, undermine a woman's autonomy and privacy in her healthcare decisions, and potentially expose providers to lawsuits from individuals who are not their patients.
Estimated impact: This provision significantly broadens the potential pool of plaintiffs who can sue abortion providers, increasing legal risk and potentially impacting the dynamics of family involvement in abortion decisions.